Background: SN38, a potent chemotherapeutic derived from irinotecan, plays a pivotal role in colorectal cancer treatment. As the active form of irinotecan, SN38 operates as an effective DNA topoisomerase I inhibitor, inducing cell death in cancer cells. Notably, SN38's potential is harnessed in Antibody-Drug Conjugates (ADCs), where it is delivered to tumor sites through innovative methods like liposomes and nanoparticles. This targeted approach enhances SN38's efficacy, emphasizing its crucial role in ADC-based strategies for precise and potent colorectal cancer therapy.
Description: PE-conjugated Anti-SN38 antibody(1G1); Rabbit mAb
Storage & Shipping: Store at 2°C-8°C for 6 months
Formulation & Reconstitution: Liquid，PBS with 0.05% Proclin300, 353% BSA
Target: SN38
Uniprot ID: N.A.
Usage: Research use only
Clone ID: 1G1
Purification: Purified from cell culture supernatant by affinity chromatography
Recommended Dilutions: Flow Cyt 1:100
Deutsch
English
